Skip to main content
. Author manuscript; available in PMC: 2024 Jun 1.
Published in final edited form as: Pain. 2022 Nov 14;164(6):1340–1354. doi: 10.1097/j.pain.0000000000002824

Figure 3. Effects of intrathecal 3-oxa-PD1 and NPD1 on CTCL-induced chronic itch and motor function.

Figure 3.

(A) NPD1 and 3-oxa-PD1 (100 ng, i.t.) significantly reduced the number of scratches, compared to vehicle (n = 13), at 1, 3 and 5 hours. Compared with NPD1 (n = 8), 3-oxa-PD1 (n = 7) produced greater inhibition of scratching at 3 and 5 hours. Two-way ANOVA with Bonferroni’s post hoc test. F(2, 25) = 120.8, P < 0.0001. **P < 0.01, ****P < 0.0001. (B) Rotarod testing showing the effects of 3-oxa-PD1 (100 ng, i.t.) on motor function in naïve animals and CTCL animals (Day 20). n = 15 mice per group. Note that fall latency is slightly increased after 3-oxa-PD1 treatment. Data are shown as mean ± SEM.